Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Ind-Ra expects revenue growth of over 12% in 2022.
Subscribe To Our Newsletter & Stay Updated
